Drugs / BG00001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00299962 | Mar 2006 → May 2008 | malignant pleural mesothelioma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00031083 | Apr 2002 → Oct 2003 | anaplastic astrocytoma, gliosarcoma, oligoastrocytoma | Biogen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG00001 | “In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients...” NCT00031083 ↗1“Ad.hIFN-β (BG00001) is a replication-defective recombinant adenoviral vector containing the human interferon-beta (hIFN-β) gene.” NCT00299962 ↗ |
| Route | Other | “will be directly injected into tumors” NCT00031083 ↗ |